SCHEMBL3520372

SCHEMBL3520372

COC(=O)c1c(N)c([N+](=O)[O-])cc(F)c1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.48
KMT2A Q03164 5/20 0.41
MAPT P10636 5/20 0.40
KDM4E B2RXH2 3/20 0.40
MEN1 O00255 3/20 0.40
MAPK1 P28482 2/20 0.40
G6PD P11413 1/20 0.40
PKM P14618 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
APOBEC3G Q9HC16 1/20 0.40
TPMT P51580 1/20 0.40
POLB P06746 1/20 0.39
ALDH1A1 P00352 2/20 0.38
LMNA P02545 2/20 0.38
ABCC4 O15439 1/20 0.38
PLIN1 O60240 1/20 0.38
CACNA1F O60840 1/20 0.38
GMNN O75496 1/20 0.38
KCNK2 O95069 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1068541 0.84 MAPT (0.50) SMN1; SMN2KMT2AMAPTKDM4EMEN1
SCHEMBL3516661 0.80 SMN1; SMN2 (0.44) SMN1; SMN2KMT2AMAPTKDM4EMEN1
SCHEMBL1868433 0.80 ALDH1A1 (0.41) SMN1; SMN2KMT2AMAPTKDM4EMEN1
SCHEMBL25367899 0.79 MAPT (0.46) SMN1; SMN2KMT2AMAPTKDM4EMEN1
SCHEMBL3520078 0.79 TDP1 (0.40) SMN1; SMN2KMT2AMAPTKDM4EMEN1
SCHEMBL1071311 0.78 KMT2A (0.43) SMN1; SMN2KMT2AMAPTKDM4EMEN1
SCHEMBL17525992 0.78 MAPT (0.45) SMN1; SMN2KMT2AMAPTKDM4EMEN1
SCHEMBL3800021 0.76 SETD7 (0.44) SMN1; SMN2KMT2AMAPTKDM4EMEN1
SCHEMBL1437423 0.75 SMN1; SMN2 (0.51) SMN1; SMN2KMT2AMAPTKDM4EMEN1
SCHEMBL7820550 0.75 CYP1A2 (0.46) SMN1; SMN2KMT2AMAPTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101983384-A Prolyl hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2011-03-02 CN disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 SMN1; SMN2 3777/4885KMT2A 300/4885MAPT 4697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.